Company intelligence / Profile preview

Braeburn Pharmaceuticals

Plymouth Meeting, Pennsylvania, United Statesbraeburnrx.com ↗

Ownership: Public · BBRX
Development stage: Commercial

Overview

FDA approved Brixadi (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder in May 2023. Previously completed Phase 3 trials for CAM2038 (now Brixadi) showing positive safety and efficacy results.

Therapeutic areas: PsychiatryNeurology
Modalities: Long-acting injectable and implantable formulations
Industry: Biotech

Drug pipeline

3 assets

CAM2038

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Camurus (for CAM2038/Brixadi development)Endo Pharmaceuticals (acquired risperidone implant technology)

Financials

Market cap: $439M
Total revenue: $65.1M
Enterprise value: $134.3M

Beyond the preview

Go deeper on Braeburn Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Braeburn Pharmaceuticals.

Explore the full profile